🔎 Trials Near Me

Hjem › T-celle-lymfom › Washington

Kliniske studier for T-celle-lymfom i Washington

6 studier for T-celle-lymfom søker deltakere på steder i Washington.

Byer i Washington

Offisiell studietekst (engelsk)

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

  • Fred Hutchinson Cancer Center, Seattle
  • University of Washington Medical Center - Montlake, Seattle
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04803201

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  • University of Washington Fred Hutch Cancer Center, Seattle
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06561048

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

  • Providence Regional Cancer System-Aberdeen, Aberdeen
  • PeaceHealth Saint Joseph Medical Center, Bellingham
  • Providence Regional Cancer System-Centralia, Centralia
  • og 16 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06724237

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • Swedish Cancer Institute, Seattle
  • Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT04104776

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

  • Fred Hutch/University of Washington Cancer Consortium, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. mai 2026 · NCT07225985

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Seattle Children's Hospital, Seattle
RekruttererFase 1
Alder 1 til 21 · Alle kjønn · Oppdatert 6. des. 2024 · NCT05476770

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.